Groundbreaking clinical study demonstrates predictive value of PD-1/PD-L1 engagement measured by QF-Pro® even in PD-L1–negative NSCLC patients

HAWK Biosystems is pleased to announce a new distribution partnership with Metrolab, a leading supplier of advanced scientific solutions based in Athens, Greece. This collaboration marks an important step in expanding access to our QF-Pro® platform and Violet 3.0 microscopy system across Greece and Cyprus.

With over 30 years of experience, Metrolab has built a strong reputation for delivering high-quality instrumentation and scientific support across sectors including Life Sciences, Pharmaceuticals, Biopharmaceuticals, Food & Beverages, Environment, and Research. Their established network and ISO-certified management system make them an ideal partner to support the growing demand for cutting-edge spatial biology technologies in the region.

Metrolab will offer sales, training, and technical support for both QF-Pro® and Violet, helping researchers and clinicians advance their understanding of the tumour microenvironment and improve predictions of therapeutic response.

“We are very pleased to welcome Metrolab to our international distributor network,” said CEO, Fernando Aguirre. “Their strong presence in the Greek and Cypriot markets and their deep commitment to scientific excellence make them a perfect fit to represent HAWK Biosystems’ technologies.”

“We are excited with the opportunity to promote, distribute and support the revolutionary HAWK Biosystems’ technologies solutions to the Scientific & Clinical Community in Greece and Cyprus” said METROLAB’s CEO Pantelis Kapetis.

This partnership supports HAWK Biosystems’ mission to make functional biomarkers and advanced spatial biology tools widely accessible to the scientific and clinical community across Europe and beyond.

To learn more about Metrolab, visit: https://www.metrolab.gr

Share this post

Skip to content